However, previous systematic reviews including any grade of AE [12, 47] reported that the number of incidence of nausea/vomiting and mucositis are more observed in IRI-based regimens without molecular targeting agents than Ox, and bleeding event and venous thromboembolism are more observed in IRI + anti-VEGF regimens compared with Ox + anti-VEGF. The gene discussed is VEGFA; the disease is venous thromboembolism.